These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 24823993)
1. Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer. Li S; He N; Li W; Wu PH Chin J Cancer; 2014 Jun; 33(6):295-305. PubMed ID: 24823993 [TBL] [Abstract][Full Text] [Related]
2. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165 [TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Kemeny N; Seiter K; Conti JA; Cohen A; Bertino JR; Sigurdson ER; Botet J; Chapman D; Mazumdar M; Budd AJ Cancer; 1994 Feb; 73(4):1134-42. PubMed ID: 8313315 [TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678 [TBL] [Abstract][Full Text] [Related]
5. Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C. Link KH; Kornmann M; Leder G; Pillasch AF; Sunelaitis E; Schatz M; Pressmar J; Beger HG Gan To Kagaku Ryoho; 1999 Feb; 26(3):269-81. PubMed ID: 10065089 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066 [TBL] [Abstract][Full Text] [Related]
7. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. Dhir M; Jones HL; Shuai Y; Clifford AK; Perkins S; Steve J; Hogg ME; Choudry MH; Pingpank JF; Holtzman MP; Zeh HJ; Bahary N; Bartlett DL; Zureikat AH Ann Surg Oncol; 2017 Jan; 24(1):150-158. PubMed ID: 27431415 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of radiofrequency ablation of unresectable metastatic colorectal cancer with hepatic arterial infusion pump chemotherapy. Martin RC; Scoggins CR; McMasters KM J Surg Oncol; 2006 Apr; 93(5):387-93. PubMed ID: 16550574 [TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. Kemeny N; Eid A; Stockman J; Gonen M; Schwartz L; Tetzlaff E; Paty P J Surg Oncol; 2005 Aug; 91(2):97-101. PubMed ID: 16028279 [TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy. Pilati P; Mammano E; Mocellin S; Tessari E; Lise M; Nitti D Anticancer Res; 2009 Oct; 29(10):4139-44. PubMed ID: 19846962 [TBL] [Abstract][Full Text] [Related]
11. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. House MG; Kemeny NE; Gönen M; Fong Y; Allen PJ; Paty PB; DeMatteo RP; Blumgart LH; Jarnagin WR; D'Angelica MI Ann Surg; 2011 Dec; 254(6):851-6. PubMed ID: 21975318 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Kemeny N; Capanu M; D'Angelica M; Jarnagin W; Haviland D; Dematteo R; Fong Y Ann Oncol; 2009 Jul; 20(7):1236-41. PubMed ID: 19233901 [TBL] [Abstract][Full Text] [Related]
13. Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Litvak DA; Wood TF; Tsioulias GJ; Chung M; Chawla SP; Foshag LJ; Morton DL; Ramming KP; Bilchik AJ Ann Surg Oncol; 2002 Mar; 9(2):148-55. PubMed ID: 11888871 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951 [TBL] [Abstract][Full Text] [Related]
15. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. Alberts SR; Roh MS; Mahoney MR; O'Connell MJ; Nagorney DM; Wagman L; Smyrk TC; Weiland TL; Lai LL; Schwarz RE; Molina R; Dentchev T; Bolton JS J Clin Oncol; 2010 Feb; 28(5):853-8. PubMed ID: 20048179 [TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis. Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400 [TBL] [Abstract][Full Text] [Related]